Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.48 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.48 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225204 | 1.00 | LAP3 (0.48) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL5404893 | 0.91 | LAP3 (0.47) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL8159887 | 0.91 | LAP3 (0.47) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| Hydrochloric Acid SCHEMBL5871977 | 0.90 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| Hydrochloric Acid SCHEMBL7322995 | 0.90 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL7319349 | 0.86 | LAP3 (0.42) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL6427941 | 0.85 | LAP3 (0.52) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL5871974 | 0.84 | PSEN1 (0.41) | LAP3ANPEPRNPEPDNPEPPSEN1 | |
| SCHEMBL5871880 | 0.84 | PSEN1 (0.41) | LAP3ANPEPRNPEPDNPEPPSEN1 | |
| SCHEMBL8568989 | 0.83 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. Searle & Co. (now G.D. Searle, LLC) (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. Searle & Co. (now G.D. Searle, LLC) (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| EP-0813867-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-0813868-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0558673-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5475027-A | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1993023368-A1 | UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | LAP3 148/4885ANPEP 9/4885RNPEP 4/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | LAP3 193/4885ANPEP 9/4885RNPEP 5/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | LAP3 170/4885ANPEP 10/4885RNPEP 5/4885 |
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | TMPRSS15, TMPRSS11D, MME | LAP3 162/4885ANPEP 12/4885RNPEP 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.